Literature DB >> 19440826

Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.

Ryo Maeda1, Noritaka Isowa, Hideyuki Onuma, Hiroshi Miura, Hirokazu Touge, Yuji Kawasaki.   

Abstract

Early-stage malignant pleural mesothelioma (MPM) is difficult for physicians to diagnose, and the disease is usually advanced at the time of diagnosis. We report a case of early-stage MPM in a 69-year-old man. The patient presented with fever and left chest pain. A computed tomography scan (CT) of the chest showed a small amount of left pleural effusion and slight left pleural thickening that remained unchanged for 1 year. One month after his inflammatory response spontaneously decreased, follow-up CT of the chest showed reduction in the effusion volume but no change in the pleural thickening. Positron emission tomography with (18)F-fluorodeoxyglucose (FDG) showed increased FDG uptake in the pleural thickening on the left side. Because MPM could not be ruled out, video-assisted thoracoscopic surgery with pleural biopsy was performed for a definitive diagnosis. The postoperative histological diagnosis was early-stage MPM classified as T1a N0M0 disease.

Entities:  

Mesh:

Year:  2009        PMID: 19440826     DOI: 10.1007/s11748-008-0353-5

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  9 in total

1.  Prognostic value of FDG PET imaging in malignant pleural mesothelioma.

Authors:  F Bénard; D Sterman; R J Smith; L R Kaiser; S M Albelda; A Alavi
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

2.  Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.

Authors:  H Kitazume; K Kitamura; K Mukai; Y Inayama; N Kawano; N Nakamura; J Sano; K Mitsui; S Yoshida; Y Nakatani
Journal:  Cancer       Date:  2000-02-25       Impact factor: 6.860

3.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

4.  Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.

Authors:  V I Adams; K K Unni; J R Muhm; J R Jett; D M Ilstrup; P E Bernatz
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

5.  The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Nelson G Ordóñez
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

6.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.

Authors:  R L Attanoos; A Griffin; A R Gibbs
Journal:  Histopathology       Date:  2003-09       Impact factor: 5.087

7.  Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.

Authors:  C Boutin; F Rey
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

8.  Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.

Authors:  C Boutin; F Rey; J Gouvernet; J R Viallat; P Astoul; V Ledoray
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

9.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.